贺昕张春驰刘辉何跃邢建丽.血塞通滴丸联合盐酸美金刚治疗阿尔茨海默病的临床研究[J].现代生物医学进展英文版,2011,11(21):4150-4152. |
血塞通滴丸联合盐酸美金刚治疗阿尔茨海默病的临床研究 |
Clinical Aesearch of Xuesaitong Diwan and Memantine HydrochlorideTreatment of Alzheimer's Disease |
|
DOI: |
中文关键词: 血塞通滴丸 盐酸美金刚 阿尔茨海默病 低密度脂蛋白胆固醇 |
英文关键词: Xuesaitong Diwan Memantine hydrochloride Alzheimer's disease |
基金项目: |
|
Hits: 660 |
Download times: 839 |
中文摘要: |
目的:分析血塞通滴丸联合盐酸美金刚治疗阿尔茨海默病(Alzheimer's disease,AD)患者的临床疗效及安全性。方法:本院就
诊的AD 患者60 例。对照组给予盐酸美金刚,观察组在对照组的基础上给予血塞通滴丸。结果:治疗后观察组MMSE、ADL及
GDS评分明显优于对照组,差异显著(P<0.05)。治疗后观察组TC、LDL-C明显少于对照组,差异显著(P<0.05)。两组均未出现明显
不良反应患者。结论:应用血塞通滴丸联合盐酸美金刚治疗AD患者近期疗效好,毒副作用少,临床价值高。 |
英文摘要: |
Objective: Analyse therapeutic effect and safety of Xuesaitong Diwan and memantine hydrochloride treatment of
Alzheimer's disease. Methods: 60 cases of patients with AD, divided into the observation group and the control group. The control group:
memantine hydrochloride, the observation group: memantine hydrochloride and Xuesaitong Diwan. Results: After treatment, MMSE,
ADL and GDS score of the observation group than in the control groups. Significant difference (P<0.05). After treatment, TC, LDL - C of
the observation group than in the control groups. Significant difference (P<0.05). Two groups did not appear harmful response. Conclusion:
Xuesaitong Diwan and memantine hydrochloride treatment of Alzheimer's disease is good efficacy, side effects less, clinical value is
high. |
View Full Text
View/Add Comment Download reader |
Close |